|
Feb 24
|
Trump’s Early Policy Moves Create New Headaches for This Biotech Heavyweight
|
|
Feb 21
|
Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
|
|
Feb 20
|
Illumina teases transcriptome profiling tech ahead of 2026 launch
|
|
Feb 19
|
Cathie Wood Explains AI Growth Catalysts for Illumina (ILMN)
|
|
Feb 19
|
Illumina unveils first-of-its-kind spatial transcriptomics technology
|
|
Feb 18
|
Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
|
|
Feb 18
|
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
|
|
Jan 8
|
ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series
|
|
Jan 7
|
Illumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications
|
|
Jan 3
|
Illumina price target lowered to $180 from $184 at Evercore ISI
|
|
Jan 3
|
Here’s Why Illumina, Inc. (ILMN) Is Among The Stocks Targeted By Activist Hedge Funds
|